Abstract
Bloodstream infection (BSI) by species of Candida has been identified as an important cause of death in patients with neutropenia who undergo chemotherapy for the treatment of hematologic malignancies This study aimed to verify the occurrence of bloodstream infections by Candida species in patients admitted to the haematology-oncology service of a public hospital specialized in the treatment of cancer in Northeast Brazil. A total of 105 clinical samples from 62 patients with haematological malignancies were analyzed at the Laboratory of Medical Mycology at the Federal University of Pernambuco. Only 7 of 105 individuals were in the ICU environment. The mycological diagnosis was performed through automation (BACTEC 9120 / PHOENIX™), proteomic identification (MALDI-TOF MS) and molecular analysis (PCR). The antifungal susceptibility test followed the bloodstream infection recommendations of Clinical Laboratory Standards Institute. Among the samples studied, nine strains (8,57%) were of the genus Candida, being six C. tropicalis and three C. albicans. The isolates were completely susceptible to the antifungal agents tested. Deaths occurred in 66,6% of the cases. Patients with hematologic malignancies hospitalized in intensive care and the state of septic shock present a higher risk of occurrence of BSI by Candida and death by this opportunistic pathogen.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
